Definium Therapeutics (DFTX) Other Accumulated Expenses (2020 - 2026)
Definium Therapeutics (DFTX) posted quarterly Other Accumulated Expenses of $604000.0 for Q1 2026, up 131.42% year-over-year from $261000.0 in Q1 2025, and up 18.43% quarter-over-quarter from $510000.0 in Q4 2025.
Powered by 
Analysis
Definium Therapeutics (DFTX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Other Accumulated Expenses for 7 consecutive years, with $604000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 131.42% year-over-year to $604000.0; the TTM figure through Mar 2026 stood at $604000.0 (up 131.42% YoY), while the FY2025 annual figure was $510000.0, up 83.45% from the prior year.
- Other Accumulated Expenses improved to $604000.0 in Q1 2026 per DFTX's latest filing, from $510000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $685000.0 in Q2 2024 and bottomed at $45000.0 in Q1 2022.
- Historically, Other Accumulated Expenses has averaged $312764.7 across 5 years, with a median of $291000.0 in 2024.
- Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 2300.0% — and 2023, when it slumped 60.53%.
- Definium Therapeutics' Other Accumulated Expenses stood at $72000.0 in 2022, then soared by 401.39% to $361000.0 in 2023, then decreased by 22.99% to $278000.0 in 2024, then soared by 83.45% to $510000.0 in 2025, then gained by 18.43% to $604000.0 in 2026.
- Business Quant data shows DFTX's Other Accumulated Expenses at $604000.0 in Q1 2026, $510000.0 in Q4 2025, and $498000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Definium Therapeutics | 4.23 Bn | 4.23 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 560,000.00 |
| Mar 31, 2026 | 604,000.00 |
| Dec 31, 2025 | 510,000.00 |
| Sep 30, 2025 | 498,000.00 |
| Jun 30, 2025 | 462,000.00 |
| Mar 31, 2025 | 261,000.00 |
| Dec 31, 2024 | 278,000.00 |
| Sep 30, 2024 | 311,000.00 |
| Jun 30, 2024 | 685,000.00 |
| Mar 31, 2024 | 291,000.00 |
| Dec 31, 2023 | 361,000.00 |
| Sep 30, 2023 | 436,000.00 |
| Jun 30, 2023 | 90,000.00 |
| Mar 31, 2023 | 92,000.00 |
| Dec 31, 2022 | 72,000.00 |
| Sep 30, 2022 | 93,000.00 |
| Jun 30, 2022 | 228,000.00 |
| Mar 31, 2022 | 45,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Dec 31, 2020 | 186,000.00 |